|
Neoplasia
Citations 321-330 of 4217 total displayed.
|
Past content
(since Jan 1997):
|
Recent major improvement in long-term survival of younger patients with multiple myeloma
- Hermann Brenner, Adam Gondos, and Dianne Pulte
Blood 2008; 111: 2521-2526.
[Abstract]
[Full text]
[PDF]
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib
- Roberto Piva, Bruce Ruggeri, Michael Williams, Giulia Costa, Ilaria Tamagno, Dario Ferrero, Valentina Giai, Marta Coscia, Silvia Peola, Massimo Massaia, Gabriella Pezzoni, Cecilia Allievi, Nicoletta Pescalli, Mara Cassin, Stefano di Giovine, Paola Nicoli, Paola de Feudis, Ivan Strepponi, Ilaria Roato, Riccardo Ferracini, Benedetta Bussolati, Giovanni Camussi, Susan Jones-Bolin, Kathryn Hunter, Hugh Zhao, Antonino Neri, Antonio Palumbo, Celia Berkers, Huib Ovaa, Alberto Bernareggi, and Giorgio Inghirami
Blood 2008; 111: 2765-2775.
[Abstract]
[Full text]
[PDF]
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia
- Rosemary E. Gale, Claire Green, Christopher Allen, Adam J. Mead, Alan K. Burnett, Robert K. Hills, and David C. Linch, on behalf of the Medical Research Council Adult Leukaemia Working Party
Blood 2008; 111: 2776-2784.
[Abstract]
[Full text]
[PDF]
Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders
- Animesh Pardanani, Brooke L. Fridley, Terra L. Lasho, D. Gary Gilliland, and Ayalew Tefferi
Blood 2008; 111: 2785-2789.
[Abstract]
[Full text]
[PDF]
Increased proteasomal degradation of Bax is a common feature of poor prognosis chronic lymphocytic leukemia
- Samir G. Agrawal, Feng-Ting Liu, Catherine Wiseman, Sima Shirali, Hongxiang Liu, Debra Lillington, Ming-Qing Du, Denise Syndercombe-Court, Adrian C. Newland, John G. Gribben, and Li Jia
Blood 2008; 111: 2790-2796.
[Abstract]
[Full text]
[PDF]
Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL
- Feng-Ting Liu, Samir G. Agrawal, John G. Gribben, Hongtao Ye, Ming-Qing Du, Adrian C. Newland, and Li Jia
Blood 2008; 111: 2797-2805.
[Abstract]
[Full text]
[PDF]
PAX2 expression by HHV-8–infected endothelial cells induced a proangiogenic and proinvasive phenotype
- Valentina Fonsato, Stefano Buttiglieri, Maria Chiara Deregibus, Benedetta Bussolati, Elisabetta Caselli, Dario Di Luca, and Giovanni Camussi
Blood 2008; 111: 2806-2815.
[Abstract]
[Full text]
[PDF]
Potentially oncogenic B-cell activation–induced smaller isoforms of FOXP1 are highly expressed in the activated B cell–like subtype of DLBCL
- Philip J. Brown, Sally L. Ashe, Ellen Leich, Christof Burek, Sharon Barrans, James A. Fenton, Andrew S. Jack, Karen Pulford, Andreas Rosenwald, and Alison H. Banham
Blood 2008; 111: 2816-2824.
[Abstract]
[Full text]
[PDF]
MicroRNA expression profiling in classic Hodgkin lymphoma
- Alfons Navarro, Anna Gaya, Antonio Martinez, Alvaro Urbano-Ispizua, Aina Pons, Olga Balagué, Bernat Gel, Pau Abrisqueta, Armando Lopez-Guillermo, Rosa Artells, Emili Montserrat, and Mariano Monzo
Blood 2008; 111: 2825-2832.
[Abstract]
[Full text]
[PDF]
Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo
- Claire M. Edwards, James R. Edwards, Seint T. Lwin, Javier Esparza, Babatunde O. Oyajobi, Brandon McCluskey, Steven Munoz, Barry Grubbs, and Gregory R. Mundy
Blood 2008; 111: 2833-2842.
[Abstract]
[Full text]
[PDF]
|
|
